J Frontier Co.,Ltd. (2934) Stock Price

J-Frontier operates primarily in the healthcare sector, managing its own brands of health supplements and pharmaceuticals through planning, development, and direct-to-consumer sales. The company also operates "SOKUYAKU," a medical platform that provides integrated services from online medical consultations and medication guidance to home delivery of prescription drugs. Originally founded as an internet advertising agency, J-Frontier leverages its sales promotion expertise to offer end-to-end services spanning sales and logistics.

The company's primary customers are individual consumers and corporate clients including medical institutions and product-handling companies. Revenue comes from direct-to-consumer sales of proprietary products, recurring membership purchases, fees from advertising and marketing services, and sales from wholesale and business process outsourcing (BPO) contracts. The company handles mail and web orders while partnering with external call centers and logistics providers to streamline payment collection and shipping.

J-Frontier divides its business into three main segments: Medical Care Sales, Healthcare Sales, and Healthcare Marketing. Medical Care Sales encompasses online consultations and medication guidance through "SOKUYAKU," prescription drug home delivery, and digital support services for medical institutions. Healthcare Sales operates direct-to-consumer sales of health supplement brands such as "Koso Suiso 328 Sen." Healthcare Marketing supports corporate clients' sales promotion through advertising services, talent casting, SNS and PR events, wholesale operations, and BPO services.

J-Frontier aims to improve revenue and EBITDA over the medium to long term. The company prioritizes QAU (quarterly active unique users), which indicates consumer usage, and ARR (annual recurring revenue), which reflects revenue generated from that user base. By expanding these metrics, the company is building a stable revenue foundation. This strategy is supported by Japan's large domestic B-to-C e-commerce market, which reached approximately 14.676 trillion yen in 2023 with an e-commerce penetration rate of 9.4%, as well as the robust health supplement market at 905 billion yen in fiscal 2023 and the over-the-counter pharmaceutical market at 710.5 billion yen in 2024. The company is focusing on expanding recurring revenue, primarily through subscription-based models.

The company's priority investment areas are strengthening its own brands in health supplements and pharmaceuticals, and expanding SOKUYAKU, its medical platform. Specific initiatives include launching new products, enhancing subscription member services, improving the quality of promotional and packaging materials, and strengthening customer support to increase satisfaction and retention rates. Regarding advertising investment, the company continuously monitors market conditions by media channel, customer response, and customer acquisition cost (CPO) for subscription customers. This enables the company to differentiate itself by balancing new customer acquisition and existing member retention through efficient ad allocation.

For new market development and business expansion, the company applies expertise in e-commerce, marketing, and logistics developed through mail-order operations to the healthcare sector. SOKUYAKU, which launched in February 2021, provides a one-stop service from online consultations and online medication guidance to home delivery of prescription drugs. Following regulatory changes such as revisions to medical reimbursement rates, the platform has rapidly expanded its partner medical institutions and user base. The company is advancing partnerships, expanding corporate services, and broadening its business scope through M&A and alliances. Additionally, the company is enhancing corporate brand value through product development aligned with the SDGs and public relations and CSR activities.

The company is also strengthening technological innovation and internal controls. It has implemented digital healthcare service applications, digitalized procedures, obtained privacy marks for personal information protection, and established information security management systems (ISMS/ISO27001) to enhance user convenience and trust. Following accounting issues identified in 2024, the company has implemented preventive measures including appointing a CFO as director, increasing external directors, conducting regular compliance training, implementing monthly profit margin monitoring, and strengthening awareness of internal reporting systems. The company is pursuing sustainable growth through both technological and governance improvements.